Skip to main content
RHYTHM PHARMACEUTICALS, INC. logo

RHYTHM PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · RYTM ISIN · US76243J1051 LEI · 529900JPNWXQ8DPLA551 US Manufacturing
Open in API
Filings indexed 775 across all filing types
Latest filing 2026-05-29 Proxy Solicitation & In…
Country US United States of America
Listing US RYTM

About RHYTHM PHARMACEUTICALS, INC.

https://rhythmtx.com/

Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on developing and commercializing precision medicines for rare genetic diseases of obesity. The company's work centers on the melanocortin-4 receptor (MC4R) pathway, a key biological system that regulates hunger and energy expenditure. Its lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved for treating severe obesity and hyperphagia (insatiable hunger) in patients with specific rare conditions, such as Bardet-Biedl syndrome. Rhythm is dedicated to advancing a portfolio of therapies that address the root cause of rare neuroendocrine diseases to improve patient outcomes.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement
2026-05-29 English
S-8 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Form S-8 Registration Statement filed with the SEC to register deferred compensation plan securities under the Securities Act of 1933. It is not an AGM presentation, earnings release, annual or interim report, or any other specified category in the list. As a general SEC registration/prospectus filing that does not fit a more specific category, it falls under the fallback “Regulatory Filings” category (RNS).
2026-05-05 English
8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
Regulatory Filings Classification · 90% confidence The document is a United States SEC Form 8-K current report furnishing an earnings press release as Exhibit 99.1. It does not contain substantive financial data itself but rather points to an attached press release. Under the taxonomy, a Form 8-K is a regulatory filing and this short announcement falls under the catch-all category for miscellaneous compliance filings rather than the earnings release category, since the actual financial details are not included in the body of the text.
2026-05-05 English
DEF 14A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
Proxy Solicitation & Information Statement
2026-04-29 English
8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
Board/Management Information Classification · 95% confidence The document is a press release announcing changes to the company's Board of Directors, specifically the appointment of a new director and the departure of an existing one. It includes biographical details about the new director and some company background information, but it does not contain financial statements, audit information, or detailed management discussion of financial results. There is no indication that this is a full annual report, earnings release, or any other financial report. The primary focus is on board changes, which fits the category of Board/Management Information (MANG). The document length is about 11,000 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Therefore, the appropriate classification is MANG with high confidence.
2026-04-03 English
SCHEDULE 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
Major Shareholding Notification
2026-03-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.